Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Pathologic Correlation of Serum Carcinoembryonic Antigen and Cytokeratin 19 Fragment in Resected Nonsmall Cell Lung Cancer

  • Lee, Seokkee (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Lee, Chang Young (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Kim, Dae Joon (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Hong, Dae Jin (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Lee, Jin Gu (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Chung, Kyung Young (Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine)
  • Received : 2012.11.07
  • Accepted : 2012.11.14
  • Published : 2013.06.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This study focused on the association between preoperative serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (Cyfra 21-1) levels and pathologic parameters in patients with resected non-small-cell lung cancer (NSCLC). Materials and Methods: The records of 527 patients who underwent pulmonary resection of NSCLC were reviewed. The association between preoperative serum CEA and Cyfra 21-1 levels and variables that had p-values of less than 0.05 in a t-test or one-way analyses of variance was analyzed by multiple linear regression. Results: The mean serum CEA and Cyfra 21-1 levels prior to surgery were $6.8{\pm}23.1$ mg/dL (range, 0.01 to 390.8 mg/dL) and $5.4{\pm}12.3$ mg/dL (range, 0.65 to 140.2 mg/dL). The serum CEA levels were associated with tumor (T) and lymph node (N) stage and histology. The serum Cyfra 21-1 levels were associated with T stage, tumor size, and histology. Multiple linear regression indicated that serum CEA levels were associated with T (T3/4 vs. T1: ${\beta}$=8.463, p=0.010) and N stage (N2/3 vs. N0: ${\beta}$=9.208, p<0.001) and histology (adenocarcinoma vs. squamous cell: ${\beta}$=6.838, p=0.001), and serum Cyfra 21-1 levels were associated with tumor size (${\beta}$=2.579, p<0.001) and histology (squamous cell vs. adenocarcinoma: ${\beta}$=4.420, p=0.020). Conclusion: Serum CEA level was correlated with T and N stage, and Cyfra 21-1 with tumor size. CEA and Cyfra 21-1 showed histologic correlation. CEA is mainly elevated in adenocarcinoma and Cyfra 21-1 in squamous cell carcinoma. These results might be helpful for predicting pathologic status in preoperative NSCLC.

Keywords

References

  1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. https://doi.org/10.1056/NEJMoa043623
  2. Horn L, Sandler AB, Putnam JB Jr, Johnson DH. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. J Thorac Oncol 2007;2:377-83. https://doi.org/10.1097/01.JTO.0000268669.64625.bb
  3. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004;90: 2097-105. https://doi.org/10.1038/sj.bjc.6601851
  4. Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002;36: 265-70. https://doi.org/10.1016/S0169-5002(02)00009-0
  5. Niklinski J, Burzykowski T, Niklinska W, et al. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 1998;12:1424-8. https://doi.org/10.1183/09031936.98.12061424
  6. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001;31:221-31. https://doi.org/10.1016/S0169-5002(00)00186-0
  7. Suzuki K, Nagai K, Yoshida J, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 1999;67:927-32. https://doi.org/10.1016/S0003-4975(99)00140-X
  8. Muley T, Dienemann H, Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 2003;23:4085-93.
  9. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-7.
  10. Muley T, Fetz TH, Dienemann H, et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer 2008;60:408-15. https://doi.org/10.1016/j.lungcan.2007.10.026
  11. Blankenburg F, Hatz R, Nagel D, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol 2008;29:272-7. https://doi.org/10.1159/000152945
  12. Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998;82:1850-9. https://doi.org/10.1002/(SICI)1097-0142(19980515)82:10<1850::AID-CNCR6>3.0.CO;2-R
  13. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:435-9. https://doi.org/10.1016/j.ejcts.2007.05.014
  14. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  15. American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 1997;156:320-32. https://doi.org/10.1164/ajrccm.156.1.ats156.1
  16. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer-v.3 [Internet]. Fort Washington: National Comprehensive Cancer Network; 2012 [cited 2011 Mar 16]. Available from: http:// www.nccn.org/.
  17. Ford CH, Stokes HJ, Newman CE. Carcinoembryonic antigen and prognosis after radical surgery for lung cancer: immunocytochemical localization and serum levels. Br J Cancer 1981;44:145-53. https://doi.org/10.1038/bjc.1981.164
  18. Vincent RG, Chu TM, Fergen TB, Ostrander M. Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer 1975;36:2069-76. https://doi.org/10.1002/cncr.2820360923
  19. Icard P, Regnard JF, Essomba A, Panebianco V, Magdeleinat P, Levasseur P. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 1994;58:811-4. https://doi.org/10.1016/0003-4975(94)90755-2
  20. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000;20:5053-8.
  21. Rubins JB, Dunitz J, Rubins HB, Maddaus MA, Niewoehner DE. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998;116:412-6. https://doi.org/10.1016/S0022-5223(98)70007-8
  22. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2004;10:76-80.
  23. Suzuki H, Ishikawa S, Satoh H, et al. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:648-52. https://doi.org/10.1016/j.ejcts.2007.06.032

Cited by

  1. Fibroblast phenotypes in different lung diseases vol.9, pp.None, 2013, https://doi.org/10.1186/s13019-014-0147-z
  2. Serum Carcinoembryonic Antigen Levels and the Risk of Whole-body Metastatic Potential in Advanced Non-small Cell Lung Cancer vol.5, pp.8, 2013, https://doi.org/10.7150/jca.9871
  3. Diagnostic Utility of Serum Cytokeratin Fragment 21-1 in Patients with Lung Cancer vol.5, pp.3, 2013, https://doi.org/10.3343/lmo.2015.5.3.143
  4. The Significance of Serum Carcinoembryonic Antigen in Lung Adenocarcinoma vol.48, pp.5, 2015, https://doi.org/10.5090/kjtcs.2015.48.5.335
  5. Spondin2 is a new prognostic biomarker for lung adenocarcinoma vol.8, pp.35, 2013, https://doi.org/10.18632/oncotarget.19577
  6. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients vol.17, pp.None, 2013, https://doi.org/10.1186/s12967-019-1828-0